ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02580955
Previous Study | Return to List | Next Study

REFLOW Study, Investigating the Efficacy of the LEGFLOW DCB in TASC C&D Fempop Lesions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02580955
Recruitment Status : Active, not recruiting
First Posted : October 20, 2015
Last Update Posted : August 13, 2018
Sponsor:
Information provided by (Responsible Party):
Flanders Medical Research Program

Brief Summary:

A physician initiated trial investigating the LEGFLOW Paclitaxel-Eluting Peripheral Balloon dilatation catheter for the treatment of femoropopliteal lesions longer than 15cm.

Objective: to evaluate the short-term outcome of the treatment by means of the LEGFLOW Paclitaxel-Eluting Peripheral BAlloon Dilattaion for the treatment of long femoropopliteal lesions (TASC C&D).


Condition or disease Intervention/treatment Phase
Peripheral Arterial Disease Device: LEGFLOW DCB Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: ReFlow Study, a Physician-initiated Trial Investigating the Efficacy of the LegFlow Paclitaxel-Eluting Peripheral Balloon Dilatation Catheter for the Treatment of Femoropopliteal Lesions Longer Than 15cm (TASC C&D Lesions).
Study Start Date : October 2015
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : January 2019

Arm Intervention/treatment
Experimental: LEGFLOW DCB
patients treated with the LEGFLOW Paclitaxel-Eluting Peripheral Balloon Dilatation Catheter
Device: LEGFLOW DCB



Primary Outcome Measures :
  1. Primary Patency at 12 months, defined as absence of a hemodynamically significant stenosis on duplex ultrasound (systolic velocity ratio no greater than 2.4) at the target lesion and without TLR within 12 months. [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Primary Patency rate at 1 & 6 month follow-up [ Time Frame: 1 month, 6 months ]
  2. Technical success [ Time Frame: during procedure, at baseline ]
  3. Freedom from TLR at 1,6 and 12-month follow-up [ Time Frame: 1 month, 6 months, 12 months ]
  4. Clinical success at follow-up, defined as an improvement of Rutherford classification at all follow-up time points [ Time Frame: 12 months ]
  5. Serious adverse events [ Time Frame: 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient presenting a score from 2 to 5 following Rutherford classification
  2. Patient is willing to comply with specified follow-up evaluations at the specified times
  3. Patient is >18 years old
  4. Patient understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
  5. Patient has a projected life expectancy of at least 12 months
  6. Prior to enrolment, the guidewire has crossed target lesion
  7. Patient is eligible for treatment with the LEGFLOW Paclitaxel-Eluting Peripheral Balloon Dilatation Catheter
  8. Male, infertile female or female of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7 days prior to study procedure
  9. De novo lesion located in the femoropopliteal arteries suitable for endovascular therapy
  10. The target lesion is located within the native femoropopliteal artery
  11. The length of the target lesion is > 150mm and considered as TASC C or D lesion according to the TASC II classification.
  12. The target lesion has angiographic evidence of stenosis > 50% or occlusion which can be passed with standard guidewire manipulation
  13. Target vessel diameter visually estimated is >4mm and <6.5 mm
  14. There is angiographic evidence of at least one-vessel-runoff to the foot, irrespective of whether or not outflow was re-established by means of previous endovascular intervention

Exclusion Criteria:

  1. Patient refusing treatment
  2. Presence of a stent in the target lesion that was placed during a previous procedure
  3. Untreated flow-limiting inflow lesions
  4. Any previous surgery in the target vessel (including prior ipsilateral crural bypass)
  5. Presence of an aortic thrombosis or significant common femoral ipsilateral stenosis
  6. Previous bypass surgery in the same limb
  7. Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated
  8. Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion site
  9. Perforation at the angioplasty site evidenced by extravasation of contrast medium
  10. Patients with known hypersensitivity to heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II
  11. Patients with uncorrected bleeding disorders
  12. Aneurysm located at the level of the SFA
  13. Non-atherosclerotic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis)
  14. Severe medical comorbidities (untreated CAD/CHF, sever COPD, metastatic malignancy, dementia, etc.) or other medical condition that would preclude compliance with the study protocol or 1-year life expectancy
  15. Major distal amputation (above the transmetatarsal) in the study limb or non-study limb
  16. Septicemia or bacteremia
  17. Ipsilateral iliac treatment before the target lesion procedure with a residual stenosis >30% or ipsilateral iliac treatment conducted after the target lesion procedure
  18. Use of thrombectomy, atherectomy or laser devices during procedure
  19. Any patient considered to be hemodynamically unstable at onset of procedure
  20. Known allergy to contrast media that cannot be adequately pre-medicated prior to the study procedure
  21. Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02580955


Locations
Belgium
OLV Hospital
Aalst, Belgium, 9300
Imelda Hospital Bonheiden
Bonheiden, Belgium, 2820
AZ Sint-Blasius
Dendermonde, Belgium, 9200
Heilig Hart Hospital
Tienen, Belgium, 3300
Sponsors and Collaborators
Flanders Medical Research Program

Responsible Party: Flanders Medical Research Program
ClinicalTrials.gov Identifier: NCT02580955     History of Changes
Other Study ID Numbers: FMRP-150527
First Posted: October 20, 2015    Key Record Dates
Last Update Posted: August 13, 2018
Last Verified: August 2018

Additional relevant MeSH terms:
Peripheral Arterial Disease
Peripheral Vascular Diseases
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases